非洲儿童疟疾疫苗候选剂R21/Matrix-M的安全性和有效性:多中心,双盲,随机的第三阶段试验
Mehreen S Datoo1, Alassane Dicko2, Halidou Tinto3
1Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Lancet (London, England)
|February 4, 2024
概括
在一项涉及四个非洲国家的4800多名儿童的第三阶段试验中,R21/ Matrix- M疟疾疫苗显示出高效和良好的耐受性. 这种有前途的疫苗为非洲撒哈拉以南地区的疟疾负担提供了新工具.
科学领域:
- 疫苗学
- 传染性疾病
- 儿童医学
背景情况:
- 在之前的2b阶段试验中,一种新的疟疾疫苗R21/Matrix-M显示出超过75%的疗效.
- 这份报告详细介绍了R21/Matrix-M在3期大规模试验中的安全性和有效性.
研究的目的:
- 评估R21/Matrix-M疟疾疫苗在儿童中的保护效果和安全性.
- 在季节性和多年性疟疾传播地区评估疫苗的有效性.
主要方法:
- 一个双盲,随机的第三阶段试验,涉及四个非洲国家的5个地点的4878名5至36个月的儿童.
- 参与者接种了三剂R21/ Matrix- M或对照狂犬病疫苗,并在12个月后接种了强剂.
- 在季节性和标准传染场的12个月后,对临床疟疾的保护效果是共同主要的终点.
主要成果:
- R21/ Matrix- M 耐受性良好,常见的副作用包括注射部位疼痛和发烧.
- 疫苗对临床疟疾的12个月疗效在季节性部位为75%,在标准部位为68%.
- 针对环球体蛋白的抗体反应与疫苗的疗效相关,在较小的儿童 (5 - 17个月) 中观察到更高的疗效.
结论:
- 针对非洲儿童的临床疟疾,R21/Matrix-M疫苗是安全且高效的.
- 这种廉价的疫苗已获得世卫组织的批准和推,
更多相关视频
相关概念视频
Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Bioavailability Study Design: Healthy Subjects Versus Patients
216
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
216
Bioequivalence studies: Biowaivers
410
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
410


